{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:23:29Z","timestamp":1793993009050,"version":"4.8.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12981-5","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T10:01:56Z","timestamp":1727690516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9165-4619","authenticated-orcid":false,"given":"Al\u00edcia Batista","family":"de Almeida Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8317-1857","authenticated-orcid":false,"given":"Vitor Kendi Tsuchiya","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0706-6929","authenticated-orcid":false,"given":"Francinny Alves","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-234X","authenticated-orcid":false,"given":"Rommel Mario Rodriguez","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"12981_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2217\/pgs.10.167","volume":"12","author":"M Scartozzi","year":"2011","unstructured":"Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, et al. 5-fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011;12:251\u201365.","journal-title":"Pharmacogenomics"},{"key":"12981_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330\u20138.","journal-title":"Nat Rev Cancer"},{"key":"12981_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","volume":"78","author":"JJ Lee","year":"2016","unstructured":"Lee JJ, Beumer JH, Chu E. Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol. 2016;78:447\u201364.","journal-title":"Cancer Chemother Pharmacol"},{"key":"12981_CR4","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1080\/17425247.2017.1316260","volume":"14","author":"K Miura","year":"2017","unstructured":"Miura K, Shima H, Takebe N, Rhie J, Satoh K, Kakugawa Y, et al. Drug delivery of oral anti-cancer fluoropyrimidine agents. Expert Opin Drug Deliv. 2017;14:1355\u201366.","journal-title":"Expert Opin Drug Deliv"},{"key":"12981_CR5","unstructured":"Dean L, Kane M. Fluorouracil therapy and DPYD genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012 [cited 2024 Jul 8]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395610\/"},{"key":"12981_CR6","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1080\/17425255.2021.2029403","volume":"17","author":"E Schmulenson","year":"2021","unstructured":"Schmulenson E, Zimmermann N, Mikus G, Joerger M, Jaehde U. Current status and future outlooks on therapeutic drug monitoring of fluorouracil. Expert Opin Drug Metab Toxicol. 2021;17:1407\u201322.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"12981_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1517\/13543776.2012.661413","volume":"22","author":"P \u00c1lvarez","year":"2012","unstructured":"\u00c1lvarez P, Marchal JA, Boulaiz H, Carrillo E, V\u00e9lez C, Rodr\u00edguez-Serrano F, et al. 5-fluorouracil derivatives: a patent review. Expert Opin Ther Pat. 2012;22:107\u201323.","journal-title":"Expert Opin Ther Pat"},{"key":"12981_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/bcp.14723","volume":"87","author":"JJ Schneider","year":"2021","unstructured":"Schneider JJ, Galettis P, Martin JH. Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine. Br J Clin Pharmacol. 2021;87:317\u201325.","journal-title":"Br J Clin Pharmacol"},{"key":"12981_CR9","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1081\/NCN-200027624","volume":"23","author":"ABP van Kuilenburg","year":"2004","unstructured":"van Kuilenburg ABP, Meinsma R, van Gennip AH. Pyrimidine degradation defects and severe 5-fluorouracil toxicity. Nucleosides Nucleotides Nucleic Acids. 2004;23:1371\u20135.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"12981_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12272-017-0979-x","volume":"41","author":"Y Wei","year":"2018","unstructured":"Wei Y, Yang P, Cao S, Zhao L. The combination of curcumin and 5-fluorouracil in cancer therapy. Arch Pharm Res. 2018;41:1\u201313.","journal-title":"Arch Pharm Res"},{"key":"12981_CR11","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.3390\/cancers14133207","volume":"14","author":"RB Diasio","year":"2022","unstructured":"Diasio RB, Offer SM. Testing for dihydropyrimidine dehydrogenase deficiency to individualize 5-fluorouracil therapy. Cancers (Basel). 2022;14:3207.","journal-title":"Cancers (Basel)"},{"key":"12981_CR12","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.2174\/092986711797287584","volume":"18","author":"X Pan","year":"2011","unstructured":"Pan X, Wang C, Wang F, Li P, Hu Z, Shan Y, et al. Development of 5-fluorouracil derivatives as anticancer agents. Curr Med Chem. 2011;18:4538\u201356.","journal-title":"Curr Med Chem"},{"issue":"Suppl 1","key":"12981_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000055262","volume":"57","author":"RA Brito","year":"1999","unstructured":"Brito RA, Medgyesy D, Zukowski TH, Royce ME, Ravandi-Kashani F, Hoff PM, et al. Fluoropyrimidines: a critical evaluation. Oncology. 1999;57(Suppl 1):2\u20138.","journal-title":"Oncology"},{"key":"12981_CR14","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00280-019-03936-w","volume":"84","author":"V Sharma","year":"2019","unstructured":"Sharma V, Gupta SK, Verma M. Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs. Cancer Chemother Pharmacol. 2019;84:1157\u201366.","journal-title":"Cancer Chemother Pharmacol"},{"key":"12981_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1258\/000456303321016150","volume":"40","author":"ABP van Kuilenburg","year":"2003","unstructured":"van Kuilenburg ABP, De Abreu RA, van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem. 2003;40:41\u20135.","journal-title":"Ann Clin Biochem"},{"key":"12981_CR16","doi-asserted-by":"publisher","first-page":"1184523","DOI":"10.3389\/fphar.2023.1184523","volume":"14","author":"A Maslarinou","year":"2023","unstructured":"Maslarinou A, Manolopoulos VG, Ragia G. Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm? Front Pharmacol. 2023;14:1184523.","journal-title":"Front Pharmacol"},{"key":"12981_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2015.11.008","volume":"54","author":"CATC Lunenburg","year":"2016","unstructured":"Lunenburg CATC, Henricks LM, Guchelaar H-J, Swen JJ, Deenen MJ, Schellens JHM, et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time. Eur J Cancer. 2016;54:40\u20138.","journal-title":"Eur J Cancer"},{"key":"12981_CR18","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","volume":"74","author":"SM Offer","year":"2014","unstructured":"Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014;74:2545\u201354.","journal-title":"Cancer Res"},{"key":"12981_CR19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1186\/s12885-024-12447-8","volume":"24","author":"FC Aquino de Moraes","year":"2024","unstructured":"Aquino de Moraes FC, Dantas Leite Pess\u00f4a FD, Duarte de Castro Ribeiro CH, Rodrigues Fernandes M, Rodr\u00edguez Burbano RM, Carneiro Dos Santos NP. Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2024;24:674.","journal-title":"BMC Cancer"},{"key":"12981_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00384-024-04668-x","volume":"39","author":"FCA de Moraes","year":"2024","unstructured":"de Moraes FCA, Kelly FA, Souza MEC, Burbano RMR. Impact of adjuvant chemotherapy on survival after pathological complete response in rectal cancer: a meta-analysis of 31,558 patients. Int J Colorectal Dis. 2024;39:96.","journal-title":"Int J Colorectal Dis"},{"key":"12981_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1517\/17425255.2015.1027684","volume":"11","author":"S Matsusaka","year":"2015","unstructured":"Matsusaka S, Lenz H-J. Pharmacogenomics of fluorouracil -based chemotherapy toxicity. Expert Opin Drug Metab Toxicol. 2015;11:811\u201321.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"12981_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/138161210790112719","volume":"16","author":"D Houtsma","year":"2010","unstructured":"Houtsma D, Guchelaar HJ, Gelderblom H. Pharmacogenetics in oncology: a promising field. Curr Pharm Des. 2010;16:155\u201363.","journal-title":"Curr Pharm Des"},{"key":"12981_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ejca.2007.01.030","volume":"43","author":"JL Yen","year":"2007","unstructured":"Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer. 2007;43:1011\u20136.","journal-title":"Eur J Cancer"},{"key":"12981_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2016.08.001","volume":"50","author":"SW Lam","year":"2016","unstructured":"Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. 2016;50:9\u201322.","journal-title":"Cancer Treat Rev"},{"key":"12981_CR25","doi-asserted-by":"publisher","first-page":"e958","DOI":"10.1200\/OP.21.00874","volume":"18","author":"K Koo","year":"2022","unstructured":"Koo K, Pasternak AL, Henry NL, Sahai V, Hertz DL. Survey of US medical oncologists\u2019 practices and beliefs regarding DPYD testing before fluoropyrimidine chemotherapy. JCO Oncol Pract. 2022;18:e958\u201365.","journal-title":"JCO Oncol Pract"},{"key":"12981_CR26","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1200\/JCO.22.02364","volume":"41","author":"SD Baker","year":"2023","unstructured":"Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, et al. DPYD testing: time to put patient safety first. J Clin Oncol. 2023;41:2701\u20135.","journal-title":"J Clin Oncol"},{"key":"12981_CR27","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/onco.13967","volume":"26","author":"BB Sharma","year":"2021","unstructured":"Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA. Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist. 2021;26:1008\u201316.","journal-title":"Oncologist"},{"key":"12981_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CK-L Lo","year":"2014","unstructured":"Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol. 2014;14:45.","journal-title":"BMC Med Res Methodol"},{"key":"12981_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"12981_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"12981_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"12981_CR32","doi-asserted-by":"crossref","first-page":"A229","DOI":"10.1136\/ejhpharm-2017-001421","volume":"26","author":"MA Fern\u00e1ndez","year":"2019","unstructured":"Fern\u00e1ndez MA, Izquierdo MM, Ramos JC, de Lope LR, Mdlcd R, Martin MM. 5PSQ-061 determination of genetic polymorphisms of the dihydropyrimidine dehydrogenase gene in real clinical practice: posological individualisation. Eur J Hosp Pharm. 2019;26:A229\u201330.","journal-title":"Eur J Hosp Pharm"},{"key":"12981_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/jpm8040045","volume":"8","author":"A Amirfallah","year":"2018","unstructured":"Amirfallah A, Calibasi Kocal G, Unal OU, Ellidokuz H, Oztop I, Basbinar Y. DPYD, TYMS and MTHFR genes polymorphism frequencies in a series of Turkish colorectal cancer patients. J Pers Med. 2018;8:45.","journal-title":"J Pers Med"},{"key":"12981_CR34","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaoncol.2015.5392","volume":"2","author":"V Boige","year":"2016","unstructured":"Boige V, Vincent M, Alexandre P, Tejpar S, Landolfi S, Le Malicot K, et al. DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial. JAMA Oncol. 2016;2:655\u201362.","journal-title":"JAMA Oncol"},{"key":"12981_CR35","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1200\/JCO.2009.25.2106","volume":"28","author":"V Boige","year":"2010","unstructured":"Boige V, Mendiboure J, Pignon J-P, Loriot M-A, Castaing M, Barrois M, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol. 2010;28:2556\u201364.","journal-title":"J Clin Oncol"},{"key":"12981_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/j.seminoncol.2017.02.008","volume":"44","author":"M Boisdron-Celle","year":"2017","unstructured":"Boisdron-Celle M, Capitain O, Faroux R, Borg C, Metges JP, Galais MP, et al. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach. Semin Oncol. 2017;44:13\u201323.","journal-title":"Semin Oncol"},{"key":"12981_CR37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/CAD.0000000000000492","volume":"28","author":"A Botticelli","year":"2017","unstructured":"Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, et al. A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient. Anticancer Drugs. 2017;28:551\u20136.","journal-title":"Anticancer Drugs"},{"key":"12981_CR38","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.1200\/JCO.2008.21.6283","volume":"27","author":"MS Braun","year":"2009","unstructured":"Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol. 2009;27:5519\u201328.","journal-title":"J Clin Oncol"},{"key":"12981_CR39","first-page":"1247","volume":"18","author":"X Cai","year":"2014","unstructured":"Cai X, Fang J-M, Xue P, Song W-F, Hu J, Gu H-L, et al. The role of IVS14\u2009+\u20091 G\u2009>\u2009A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report. Eur Rev Med Pharmacol Sci. 2014;18:1247\u201358.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"12981_CR40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.17305\/bjbms.2010.2712","volume":"10","author":"T Ceri\u0107","year":"2010","unstructured":"Ceri\u0107 T, Obrali\u0107 N, Kapur-Pojski\u0107 L, Maci\u0107 D, Be\u0161lija S, Pa\u0161i\u0107 A, et al. Investigation of IVS14\u2009+\u20091G\u2009>\u2009A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-fluorouracil and capecitabine. Bosn J Basic Med Sci. 2010;10:133\u20139.","journal-title":"Bosn J Basic Med Sci"},{"key":"12981_CR41","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.18632\/oncotarget.23559","volume":"9","author":"C Cremolini","year":"2018","unstructured":"Cremolini C, Del Re M, Antoniotti C, Lonardi S, Bergamo F, Loupakis F, et al. DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Oncotarget. 2018;9:7859\u201366.","journal-title":"Oncotarget"},{"key":"12981_CR42","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1158\/1078-0432.CCR-10-2209","volume":"17","author":"MJ Deenen","year":"2011","unstructured":"Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res. 2011;17:3455\u201368.","journal-title":"Clin Cancer Res"},{"key":"12981_CR43","first-page":"68","volume":"34","author":"S Detailleur","year":"2021","unstructured":"Detailleur S, Segelov E, Re MD, Prenen H. Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study. Ann Gastroenterol. 2021;34:68\u201372.","journal-title":"Ann Gastroenterol"},{"key":"12981_CR44","first-page":"125","volume":"137","author":"D Dhawan","year":"2013","unstructured":"Dhawan D, Panchal H, Shukla S, Padh H. Genetic variability & chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: a preliminary study. Indian J Med Res. 2013;137:125\u20139.","journal-title":"Indian J Med Res"},{"key":"12981_CR45","doi-asserted-by":"publisher","first-page":"e0175998","DOI":"10.1371\/journal.pone.0175998","volume":"12","author":"M-C Etienne-Grimaldi","year":"2017","unstructured":"Etienne-Grimaldi M-C, Boyer J-C, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, et al. New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS ONE. 2017;12:e0175998.","journal-title":"PLoS ONE"},{"key":"12981_CR46","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/bcp.12631","volume":"80","author":"FS Falvella","year":"2015","unstructured":"Falvella FS, Cheli S, Martinetti A, Mazzali C, Iacovelli R, Maggi C, et al. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br J Clin Pharmacol. 2015;80:581\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"12981_CR47","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/ijc.29025","volume":"136","author":"TK Froehlich","year":"2015","unstructured":"Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiad\u00e8r CR. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer. 2015;136:730\u20139.","journal-title":"Int J Cancer"},{"key":"12981_CR48","doi-asserted-by":"publisher","first-page":"e4003","DOI":"10.1371\/journal.pone.0004003","volume":"3","author":"E Gross","year":"2008","unstructured":"Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein H-G, et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS ONE. 2008;3:e4003.","journal-title":"PLoS ONE"},{"key":"12981_CR49","doi-asserted-by":"publisher","first-page":"e78053","DOI":"10.1371\/journal.pone.0078053","volume":"8","author":"BA Jennings","year":"2013","unstructured":"Jennings BA, Loke YK, Skinner J, Keane M, Chu GS, Turner R, et al. Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PLoS ONE. 2013;8:e78053.","journal-title":"PLoS ONE"},{"key":"12981_CR50","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00280-015-2698-7","volume":"75","author":"M Joerger","year":"2015","unstructured":"Joerger M, Huitema ADR, Boot H, Cats A, Doodeman VD, Smits PHM, et al. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol. 2015;75:763\u201372.","journal-title":"Cancer Chemother Pharmacol"},{"key":"12981_CR51","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1177\/147323001003800313","volume":"38","author":"MH Kristensen","year":"2010","unstructured":"Kristensen MH, Pedersen PL, Melsen GV, Ellehauge J, Mejer J. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. J Int Med Res. 2010;38:870\u201383.","journal-title":"J Int Med Res"},{"key":"12981_CR52","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1158\/1078-0432.CCR-06-0320","volume":"12","author":"R Largillier","year":"2006","unstructured":"Largillier R, Etienne-Grimaldi M-C, Formento J-L, Ciccolini J, Nebbia J-F, Ginot A, et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res. 2006;12:5496\u2013502.","journal-title":"Clin Cancer Res"},{"key":"12981_CR53","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1038\/bjc.2013.262","volume":"108","author":"A Loganayagam","year":"2013","unstructured":"Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer. 2013;108:2505\u201315.","journal-title":"Br J Cancer"},{"key":"12981_CR54","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","volume":"5","author":"A Morel","year":"2006","unstructured":"Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006;5:2895\u2013904.","journal-title":"Mol Cancer Ther"},{"key":"12981_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00280-017-3478-3","volume":"81","author":"NA Nahid","year":"2018","unstructured":"Nahid NA, Apu MNH, Islam MR, Shabnaz S, Chowdhury SM, Ahmed MU, et al. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. Cancer Chemother Pharmacol. 2018;81:119\u201329.","journal-title":"Cancer Chemother Pharmacol"},{"key":"12981_CR56","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1186\/s12885-020-06904-3","volume":"20","author":"R Negarandeh","year":"2020","unstructured":"Negarandeh R, Salehifar E, Saghafi F, Jalali H, Janbabaei G, Abdhaghighi MJ, et al. Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. BMC Cancer. 2020;20:560.","journal-title":"BMC Cancer"},{"key":"12981_CR57","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2013.51.1857","volume":"32","author":"D Rosmarin","year":"2014","unstructured":"Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32:1031\u20139.","journal-title":"J Clin Oncol"},{"key":"12981_CR58","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/bjc.2017.289","volume":"117","author":"A Ruzzo","year":"2017","unstructured":"Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, et al. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. Br J Cancer. 2017;117:1269\u201377.","journal-title":"Br J Cancer"},{"key":"12981_CR59","first-page":"325","volume":"17","author":"J Salgado","year":"2007","unstructured":"Salgado J, Zabalegui N, Gil C, Monreal I, Rodr\u00edguez J, Garc\u00eda-Foncillas J. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep. 2007;17:325\u20138.","journal-title":"Oncol Rep"},{"key":"12981_CR60","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/01.GIM.0000118061.66602.A5","volume":"6","author":"N Salgueiro","year":"2004","unstructured":"Salgueiro N, Veiga I, Fragoso M, Sousa O, Costa N, Pellon ML, et al. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-fluorouracil toxicity in Portuguese colorectal cancer patients. Genet Med. 2004;6:102\u20137.","journal-title":"Genet Med"},{"key":"12981_CR61","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1200\/JCO.2006.10.4182","volume":"26","author":"M Schwab","year":"2008","unstructured":"Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group. JCO. 2008;26:2131\u20138.","journal-title":"JCO"},{"key":"12981_CR62","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/cpt.1257","volume":"105","author":"G Toffoli","year":"2019","unstructured":"Toffoli G, Innocenti F, Polesel J, De Mattia E, Sartor F, Dalle Fratte C, et al. The genotype for DPYD risk variants in patients with colorectal cancer and the related toxicity management costs in clinical practice. Clin Pharmacol Ther. 2019;105:994\u20131002.","journal-title":"Clin Pharmacol Ther"},{"key":"12981_CR63","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1002\/ijc.29654","volume":"137","author":"G Toffoli","year":"2015","unstructured":"Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S, et al. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. Int J Cancer. 2015;137:2971\u201380.","journal-title":"Int J Cancer"},{"key":"12981_CR64","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41397-020-00203-7","volume":"21","author":"C Vivaldi","year":"2021","unstructured":"Vivaldi C, Crucitta S, Catanese S, Cucchiara F, Arrigoni E, Pecora I, et al. Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. Pharmacogenomics J. 2021;21:233\u201342.","journal-title":"Pharmacogenomics J"},{"key":"12981_CR65","doi-asserted-by":"publisher","first-page":"ix8","DOI":"10.1093\/annonc\/mdv518.13","volume":"26","author":"S Ohnuma","year":"2015","unstructured":"Ohnuma S, Toshima M, Miura K, Kudoh K, Ishida M, Karasawa H, et al. 38P single-nucleotide polymorphisms of DPYD predict adverse events associated with 5-fluorouracil in patients with gastrointestinal cancer. Ann Oncol. 2015;26:ix8.","journal-title":"Ann Oncol"},{"key":"12981_CR66","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.annonc.2023.04.260","volume":"34","author":"A Ghoche","year":"2023","unstructured":"Ghoche A, Zadjali SA, Omar R, Osman A, Barwani HA, Mahrouqi NA, et al. P-204 DPYD gene variants and chemotherapy-induced toxicity in Omani patients with gastrointestinal tumors. Ann Oncol. 2023;34:S88.","journal-title":"Ann Oncol"},{"key":"12981_CR67","doi-asserted-by":"publisher","first-page":"dju298","DOI":"10.1093\/jnci\/dju298","volume":"106","author":"AM Lee","year":"2014","unstructured":"Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106:dju298.","journal-title":"J Natl Cancer Inst"},{"key":"12981_CR68","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1200\/OP.20.00553","volume":"16","author":"F Innocenti","year":"2020","unstructured":"Innocenti F, Mills SC, Sanoff H, Ciccolini J, Lenz H-J, Milano G. All you need to know about DPYD genetic testing for patients treated with fluorouracil and capecitabine: a practitioner-friendly guide. JCO Oncol Pract. 2020;16:793\u20138.","journal-title":"JCO Oncol Pract"},{"key":"12981_CR69","doi-asserted-by":"crossref","unstructured":"Hertz DL, Glatz A, Pasternak AL, Lonigro RJ, Vats P, Wu Y-M et al. Integration of germline pharmacogenetics into a tumor sequencing program. JCO Precis Oncol. 2018;2:PO.18.00011.","DOI":"10.1200\/PO.18.00011"},{"key":"12981_CR70","doi-asserted-by":"crossref","unstructured":"Ly RC, Schmidt RE, Kiel PJ, Pratt VM, Schneider BP, Radovich M et al. Severe capecitabine toxicity associated with a rare DPYD variant identified through whole-genome sequencing. JCO Precis Oncol. 2020;4:PO.20.00067.","DOI":"10.1200\/PO.20.00067"},{"key":"12981_CR71","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/bcpt.13782","volume":"131","author":"NH Paulsen","year":"2022","unstructured":"Paulsen NH, Vojdeman F, Andersen SE, Bergmann TK, Ewertz M, Plomgaard P, et al. DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview. Basic Clin Pharmacol Toxicol. 2022;131:325\u201346.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"12981_CR72","doi-asserted-by":"publisher","first-page":"dju351","DOI":"10.1093\/jnci\/dju351","volume":"106","author":"F Innocenti","year":"2014","unstructured":"Innocenti F. DPYD variants to predict 5-FU toxicity: the ultimate proof. J Natl Cancer Inst. 2014;106:dju351.","journal-title":"J Natl Cancer Inst"},{"key":"12981_CR73","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2217\/pme-2021-0047","volume":"19","author":"M Cevik","year":"2022","unstructured":"Cevik M, Namal E, Sener ND, Koksal UI, Cagatay P, Deliorman G, et al. Investigation of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil related toxicities in colorectal cancer. Per Med. 2022;19:435\u201344.","journal-title":"Per Med"},{"key":"12981_CR74","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103:210\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"12981_CR75","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","volume":"28","author":"CATC Lunenburg","year":"2020","unstructured":"Lunenburg CATC, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet. 2020;28:508\u201317.","journal-title":"Eur J Hum Genet"},{"key":"12981_CR76","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","volume":"19","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19:1459\u201367.","journal-title":"Lancet Oncol"},{"key":"12981_CR77","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2217\/pgs.15.70","volume":"16","author":"LM Henricks","year":"2015","unstructured":"Henricks LM, Lunenburg CATC, Meulendijks D, Gelderblom H, Cats A, Swen JJ, et al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015;16:1277\u201386.","journal-title":"Pharmacogenomics"},{"key":"12981_CR78","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10549-019-05144-9","volume":"175","author":"C Stavraka","year":"2019","unstructured":"Stavraka C, Pouptsis A, Okonta L, DeSouza K, Charlton P, Kapiris M, et al. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients. Breast Cancer Res Treat. 2019;175:511\u20137.","journal-title":"Breast Cancer Res Treat"},{"key":"12981_CR79","first-page":"89","volume":"10","author":"MW Saif","year":"2013","unstructured":"Saif MW. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD. Cancer Genomics Proteom. 2013;10:89\u201392.","journal-title":"Cancer Genomics Proteom"},{"key":"12981_CR80","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.2147\/PGPM.S337147","volume":"14","author":"C White","year":"2021","unstructured":"White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Ackland S. Ethnic diversity of DPD activity and the DPYD gene: review of the literature. PGPM. 2021;14:1603\u201317.<\\\/p>","journal-title":"PGPM"},{"key":"12981_CR81","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","volume":"105","author":"M-A Loriot","year":"2018","unstructured":"Loriot M-A, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, et al. Dihydropyrimidine d\u00e9hydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks. Bull Cancer. 2018;105:397\u2013407.","journal-title":"Bull Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12981-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12981-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12981-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T22:53:59Z","timestamp":1727736839000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12981-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12981"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12981-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was required for this systematic review with meta-analysis, as all data were already published in peer-reviewed journals. Furthermore, no patients or animals were involved in the design, conduct, or interpretation of our study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not aplicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1210"}}